#neoadjuvant — Thursday, July 23, 2026 (1 items)
| 0 | ℹ |
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
(nejm.org)
|
New England Journal of Medicine 2026-07-23 | #clinical trial #immunotherapy #bladder cancer #chemotherapy #neoadjuvant |